Diamyd Medical halts DIAGNODE-3 phase 3 retogatein trial after interim analysis misses primary endpoint

• Diamyd Medical ended its Phase 3 DIAGNODE-3 trial of retogatein in newly diagnosed Type 1 diabetes following an interim analysis already completed.
• The primary efficacy assessment did not show a clear clinical benefit, triggering the study’s pre-set futility criteria.
• No new safety concerns emerged in the interim review or in subsequent internal and external evaluations.
• The post-analysis review found no single execution or design issue, pointing instead to several potential factors for future study planning.
• The group kept its Umeå GMP facility operating while it weighs strategic options for retogatein, GAD65 manufacturing, and potential partnerships.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Diamyd Medical AB published the original content used to generate this news brief via Cision (Ref. ID: 202607270200BITN____UKPR__SV_20260726-BIT-1843-0) on July 27, 2026, and is solely responsible for the information contained therein.